Recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions, where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
In a video interview, Dr. Thomas Grace, Medical Director at the Blanchard Valley Diabetes Center in Findlay, Ohio, describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in his clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
Latest Research in Diabetes Technology: Highlights from ATTD 2022
Recap of real-time continuous glucose monitoring (rtCGM) abstracts from the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) – where innovation in diabetes medicines and treatments, cutting-edge technologies, and the latest research is presented. These abstracts are pertinent to managed care and payer decision makers and help characterize the value of rtCGM in improving clinical outcomes, decreasing avoidable healthcare utilization, and decreasing the burden of diabetes care management.
As part of a new series of video resources hosted on ManagedCareCGM.com, Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP), offers her insights on progressive approaches to diabetes coverage and management. She shares HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level and enhanced access among patients with diabetes who are prescribed any insulin or ≥3 non-insulin medications. Findings from the MOBILE study—on which Ms. Kruger served as an investigator/author—are also detailed, including the benefits associated with real-time CGM (rtCGM) in type 2 diabetes (T2D) for improving glycemic control and meeting quality measures; these findings were particularly noteworthy considering a racially and ethnically diverse study population representing traditionally underserved demographics of patients. A post hoc analysis from MOBILE is likewise discussed, along with its implications for using rtCGM to improve T2D management among Medicare beneficiaries.
The American Diabetes Association (ADA) Standards of Medical Care represent the latest evidence-based recommendations for guiding clinical practice. According to the most recent edition of these guidelines, Level A evidence from the MOBILE study supports the use of real time continuous glucose monitoring (rtCGM) in patients with insulin-treated type 2 diabetes (T2D) regardless of regimen. The findings from the MOBILE study likewise demonstrate the value of rtCGM across typically underserved demographics of patients impacted by social determinants of health (SDOH). Taking the ADA recommendations into consideration, payers are formulating coverage policies that facilitate appropriate access to rtCGM, improved outcomes in T2D, and proven per-member-per-month (PMPM) cost savings.
Published: September 2021
Released: September, 2021
Released: June, 2021
Source: Improving Quality Metrics and Reducing Cost of Care with Access to Real-Time Continuous Glucose Monitoring, a symposium at the Academy of Managed Care Pharmacy 2021 Virtual Annual Meeting.
Featuring expert faculty:
Jeffrey Dunn, PharmD, MBA
Maria Lopes, MD, MS
Janet B. McGill, MD, MA, FACE, FACP
Vanita Pindolia, PharmD, BCPS, MBA